Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Exclusion criteria

• . History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage bladder cancer, or low-grade endometrial cancer Malignancies that have undergone a putative surgical cure (ie, localized prostate cancer post-prostatectomy) within 5 years prior to Day 1 may be discussed with the Medical Monitor
• . History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug.
• . Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding
• . Clinically significant gastrointestinal abnormalities that may affect absorption of the investigational product
• . Presence of uncontrolled infection.
• . Prolongation of corrected QT interval (QTc) \> 480 milliseconds. On antiarrhythmics or medications known to prolong QT interval
• . History of any one or more of the following cardiovascular conditions within the past 6 months:
• . Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥ 140 mmHg or diastolic blood pressure (DBP) of ≥ 90mm Hg\].